A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
The unexpected approval of Vyondys 53 followed an FDA power struggle, and turned on a vague commitment from Sarepta, it has emerged.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
The second half of 2019 saw half as many innovative medical devices approved as the first.
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.